TNF Pharmaceuticals (TNFA)

Executive Summary

TNF Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for autoimmune, inflammatory, and age-related diseases. Its lead candidate, MYMD-1, is a next-generation oral TNF-alpha inhibitor designed to address conditions such as sarcopenia, rheumatoid arthritis, and central nervous system disorders. Unlike traditional TNF blockers, MYMD-1 targets the downstream production of TNF-alpha, potentially reducing immunosuppressive side effects. The company is also advancing Supera-CBD, a high-potency synthetic CBD analog for pain, anxiety, and epilepsy, which may offer improved bioavailability and efficacy over natural CBD. Both programs address large markets with significant unmet medical needs. As a private company with a public ticker (TNFA), TNF Pharmaceuticals is poised to leverage its differentiated pipeline in the competitive landscape of inflammation and neurodegeneration. The lead program's early clinical data suggest a favorable safety profile, positioning the company for potential partnership or regulatory milestones in the near term.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline results for MYMD-1 in sarcopenia40% success
• Q2 2026FDA IND clearance for Supera-CBD60% success
• Q4 2026Strategic partnership or licensing deal for MYMD-130% success